Home / Health / New Zealand Approves Party Drug for Severe PTSD Therapy
New Zealand Approves Party Drug for Severe PTSD Therapy
4 Sep
Summary
- Two psychiatrists received approval to prescribe MDMA for severe PTSD.
- New Zealand is the second country globally to approve this treatment.
- MDMA-assisted treatment will be combined with psychotherapy.
In a landmark decision, New Zealand's pharmaceutical regulatory body, Medsafe, has approved the prescription of pharmaceutical-grade MDMA for individuals suffering from severe post-traumatic stress disorder (PTSD). This groundbreaking move, effective Friday, positions New Zealand as only the second nation globally to sanction this novel treatment, following Australia's approval in 2023.
Deputy Prime Minister David Seymour emphasized the transformative potential of this decision, stating, "PTSD ruins lives and is difficult to treat." He further elaborated that MDMA, when utilized within psychedelic-assisted therapy, demonstrates significant effectiveness. New Zealand remains dedicated to broadening access to such innovative therapeutic options.
PTSD, a condition often arising from exposure to traumatic events, has historically presented treatment challenges. While clinical trials continue in the United States, where the FDA previously rejected medicinal MDMA use, New Zealand's approach signals a commitment to exploring alternative therapies. This MDMA-assisted treatment will be integrated with psychotherapy and administered exclusively in controlled clinical settings under the supervision of authorized psychiatrists, with patients needing to be 18 or older.
